Pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the Omicron wave: a multicentric retrospective study of SFGM-TC
Abstract Since the emergence of the Omicron variant of SARS-CoV-2, though considered less virulent, hospitalization and death rates among immunocompromised patients remain high, especially for poor responders to vaccination. We conducted a retrospective multicentric study to evaluate pre-exposure pr...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-11-01
|
| Series: | Journal of Hematology & Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13045-022-01387-0 |
| _version_ | 1811207930510311424 |
|---|---|
| author | Ludovic Jondreville Maud D’Aveni Hélène Labussière-Wallet Amandine Le Bourgeois Alban Villate Ana Berceanu Silvia-Maria Bezsera Anne Thiebaut Marion Boissard-Simonet Marlène Legrand Jérôme Cornillon Marie-Thérèse Rubio Patrice Chevallier Stéphanie Nguyen |
| author_facet | Ludovic Jondreville Maud D’Aveni Hélène Labussière-Wallet Amandine Le Bourgeois Alban Villate Ana Berceanu Silvia-Maria Bezsera Anne Thiebaut Marion Boissard-Simonet Marlène Legrand Jérôme Cornillon Marie-Thérèse Rubio Patrice Chevallier Stéphanie Nguyen |
| author_sort | Ludovic Jondreville |
| collection | DOAJ |
| description | Abstract Since the emergence of the Omicron variant of SARS-CoV-2, though considered less virulent, hospitalization and death rates among immunocompromised patients remain high, especially for poor responders to vaccination. We conducted a retrospective multicentric study to evaluate pre-exposure prophylaxis with AZD7442 (tixagevimab/cilgavimab) for preventing COVID-19 in adult allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. Among the 161 patients of our cohort, 22 (14%) contracted COVID-19 after a median follow-up of 105 days, but no severe form was observed. Only one major adverse event was reported: an acute coronary syndrome, resolved without sequelae. Pending randomized controlled trial results, our data support the use of AZD7442 as pre-exposure prophylaxis for COVID-19 during Omicron wave in allo-HSCT patients who failed to develop humoral immunity to vaccination, to prevent severe and potentially lethal forms of SARS-CoV-2 infection. |
| first_indexed | 2024-04-12T04:13:30Z |
| format | Article |
| id | doaj.art-a352ce7b4ede4af587b80a35a6709f9c |
| institution | Directory Open Access Journal |
| issn | 1756-8722 |
| language | English |
| last_indexed | 2024-04-12T04:13:30Z |
| publishDate | 2022-11-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Hematology & Oncology |
| spelling | doaj.art-a352ce7b4ede4af587b80a35a6709f9c2022-12-22T03:48:27ZengBMCJournal of Hematology & Oncology1756-87222022-11-011511410.1186/s13045-022-01387-0Pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the Omicron wave: a multicentric retrospective study of SFGM-TCLudovic Jondreville0Maud D’Aveni1Hélène Labussière-Wallet2Amandine Le Bourgeois3Alban Villate4Ana Berceanu5Silvia-Maria Bezsera6Anne Thiebaut7Marion Boissard-Simonet8Marlène Legrand9Jérôme Cornillon10Marie-Thérèse Rubio11Patrice Chevallier12Stéphanie Nguyen13Department of Clinical Hematology, Groupe Hospitalier Pitié-Salpêtrière, AP-HP Sorbonne UniversitéDepartment of Clinical Hematology, Centre Hospitalier Régional Universitaire de NancyDepartment of Clinical Hematology, Centre Hospitalier Lyon-Sud, Hospices Civils de LyonDepartment of Clinical Hematology, Nantes University HospitalDepartment of Clinical Hematology, Centre Hospitalier Régional Universitaire de ToursDepartment of Clinical Hematology, Besançon University HospitalInstitut de Cancérologie Lucien NeuwirthDepartment of Clinical Hematology, Centre Hospitalier Universitaire Grenoble-AlpesDepartment of Clinical Hematology, Besançon University HospitalDepartment of Clinical Hematology, Centre Hospitalier Lyon-Sud, Hospices Civils de LyonInstitut de Cancérologie Lucien NeuwirthDepartment of Clinical Hematology, Centre Hospitalier Régional Universitaire de NancyDepartment of Clinical Hematology, Nantes University HospitalDepartment of Clinical Hematology, Groupe Hospitalier Pitié-Salpêtrière, AP-HP Sorbonne UniversitéAbstract Since the emergence of the Omicron variant of SARS-CoV-2, though considered less virulent, hospitalization and death rates among immunocompromised patients remain high, especially for poor responders to vaccination. We conducted a retrospective multicentric study to evaluate pre-exposure prophylaxis with AZD7442 (tixagevimab/cilgavimab) for preventing COVID-19 in adult allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. Among the 161 patients of our cohort, 22 (14%) contracted COVID-19 after a median follow-up of 105 days, but no severe form was observed. Only one major adverse event was reported: an acute coronary syndrome, resolved without sequelae. Pending randomized controlled trial results, our data support the use of AZD7442 as pre-exposure prophylaxis for COVID-19 during Omicron wave in allo-HSCT patients who failed to develop humoral immunity to vaccination, to prevent severe and potentially lethal forms of SARS-CoV-2 infection.https://doi.org/10.1186/s13045-022-01387-0SARS-CoV-2Allogeneic stem cell transplantationPre-exposure prophylaxisAZD7442 |
| spellingShingle | Ludovic Jondreville Maud D’Aveni Hélène Labussière-Wallet Amandine Le Bourgeois Alban Villate Ana Berceanu Silvia-Maria Bezsera Anne Thiebaut Marion Boissard-Simonet Marlène Legrand Jérôme Cornillon Marie-Thérèse Rubio Patrice Chevallier Stéphanie Nguyen Pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the Omicron wave: a multicentric retrospective study of SFGM-TC Journal of Hematology & Oncology SARS-CoV-2 Allogeneic stem cell transplantation Pre-exposure prophylaxis AZD7442 |
| title | Pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the Omicron wave: a multicentric retrospective study of SFGM-TC |
| title_full | Pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the Omicron wave: a multicentric retrospective study of SFGM-TC |
| title_fullStr | Pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the Omicron wave: a multicentric retrospective study of SFGM-TC |
| title_full_unstemmed | Pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the Omicron wave: a multicentric retrospective study of SFGM-TC |
| title_short | Pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the Omicron wave: a multicentric retrospective study of SFGM-TC |
| title_sort | pre exposure prophylaxis with tixagevimab cilgavimab azd7442 prevents severe sars cov 2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the omicron wave a multicentric retrospective study of sfgm tc |
| topic | SARS-CoV-2 Allogeneic stem cell transplantation Pre-exposure prophylaxis AZD7442 |
| url | https://doi.org/10.1186/s13045-022-01387-0 |
| work_keys_str_mv | AT ludovicjondreville preexposureprophylaxiswithtixagevimabcilgavimabazd7442preventsseveresarscov2infectioninrecipientsofallogeneichematopoieticstemcelltransplantationduringtheomicronwaveamulticentricretrospectivestudyofsfgmtc AT mauddaveni preexposureprophylaxiswithtixagevimabcilgavimabazd7442preventsseveresarscov2infectioninrecipientsofallogeneichematopoieticstemcelltransplantationduringtheomicronwaveamulticentricretrospectivestudyofsfgmtc AT helenelabussierewallet preexposureprophylaxiswithtixagevimabcilgavimabazd7442preventsseveresarscov2infectioninrecipientsofallogeneichematopoieticstemcelltransplantationduringtheomicronwaveamulticentricretrospectivestudyofsfgmtc AT amandinelebourgeois preexposureprophylaxiswithtixagevimabcilgavimabazd7442preventsseveresarscov2infectioninrecipientsofallogeneichematopoieticstemcelltransplantationduringtheomicronwaveamulticentricretrospectivestudyofsfgmtc AT albanvillate preexposureprophylaxiswithtixagevimabcilgavimabazd7442preventsseveresarscov2infectioninrecipientsofallogeneichematopoieticstemcelltransplantationduringtheomicronwaveamulticentricretrospectivestudyofsfgmtc AT anaberceanu preexposureprophylaxiswithtixagevimabcilgavimabazd7442preventsseveresarscov2infectioninrecipientsofallogeneichematopoieticstemcelltransplantationduringtheomicronwaveamulticentricretrospectivestudyofsfgmtc AT silviamariabezsera preexposureprophylaxiswithtixagevimabcilgavimabazd7442preventsseveresarscov2infectioninrecipientsofallogeneichematopoieticstemcelltransplantationduringtheomicronwaveamulticentricretrospectivestudyofsfgmtc AT annethiebaut preexposureprophylaxiswithtixagevimabcilgavimabazd7442preventsseveresarscov2infectioninrecipientsofallogeneichematopoieticstemcelltransplantationduringtheomicronwaveamulticentricretrospectivestudyofsfgmtc AT marionboissardsimonet preexposureprophylaxiswithtixagevimabcilgavimabazd7442preventsseveresarscov2infectioninrecipientsofallogeneichematopoieticstemcelltransplantationduringtheomicronwaveamulticentricretrospectivestudyofsfgmtc AT marlenelegrand preexposureprophylaxiswithtixagevimabcilgavimabazd7442preventsseveresarscov2infectioninrecipientsofallogeneichematopoieticstemcelltransplantationduringtheomicronwaveamulticentricretrospectivestudyofsfgmtc AT jeromecornillon preexposureprophylaxiswithtixagevimabcilgavimabazd7442preventsseveresarscov2infectioninrecipientsofallogeneichematopoieticstemcelltransplantationduringtheomicronwaveamulticentricretrospectivestudyofsfgmtc AT mariethereserubio preexposureprophylaxiswithtixagevimabcilgavimabazd7442preventsseveresarscov2infectioninrecipientsofallogeneichematopoieticstemcelltransplantationduringtheomicronwaveamulticentricretrospectivestudyofsfgmtc AT patricechevallier preexposureprophylaxiswithtixagevimabcilgavimabazd7442preventsseveresarscov2infectioninrecipientsofallogeneichematopoieticstemcelltransplantationduringtheomicronwaveamulticentricretrospectivestudyofsfgmtc AT stephanienguyen preexposureprophylaxiswithtixagevimabcilgavimabazd7442preventsseveresarscov2infectioninrecipientsofallogeneichematopoieticstemcelltransplantationduringtheomicronwaveamulticentricretrospectivestudyofsfgmtc |